Sandoz, the world's second largest generic medicine company, is still mulling its options for owning a plant in Russia, company chief Jeff George said in an interview.
“Russia, being one of our top markets, is a very important, strategic market for investment in the future,” he said in an interview at the end of last month. “We are currently evaluating what is the right way to invest.”
Sandoz and Novartis, its parent company, are still seeking guidance from government officials as they look to develop more concrete plans, he said.
Switzerland-based Novartis, which is Russia’s biggest pharmaceutical company in terms of sales, wanted to make a decision within two or three years, the company’s chief Daniel Vasella said in January. It first announced the idea to buy or build a drug-making plant in Russia in 2008.
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.